ClinicalTrials.gg
CompletedNCT03693612Updated Aug 28, 2024Results posted

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

A Phase 1/2 interventional study of feladilimab and Tremelimumab in Neoplasms, sponsored by GlaxoSmithKline. Completed at 8 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-28.

Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous Cell Carcinomas (HNSCC) to warrant further clinical investigation (Part 2). Part 1 (dose escalation) will enroll subjects with advanced, selected solid tumors. Subjects will receive escalating doses of GSK3359609 and tremelimumab in combination in Part 1. Part 2 is randomized expansion and will enroll subjects with R/R HNSCC who have disease progression after receiving at least 1 platinum-based chemotherapy and at least 1 anti-programmed death receptor protein-1 (PD-1)/anti-programmed death-ligand 1 (PD-L1) therapy, whether in combination or separately. In Part 2, subjects will be randomized in a ratio of 2:1 to receive either GSK3359609 in combination with tremelimumab at the recommended Phase 2 dose or investigators choice of a single-agent standard of care (SOC) therapy including paclitaxel, docetaxel or cetuximab. The total duration of subjects in the study will be approximately 4 years.

02

Conditions studied

  • Neoplasms

Keywords

  • advanced solid tumor
  • Head and Neck Squamous Cell Carcinoma
  • standard of care
  • GSK3359609
  • urothelial carcinoma of the upper and lower urinary tract
  • non-small cell lung cancer
  • cutaneous melanoma
  • Tremelimumab
  • clear cell renal carcinoma
  • castrate resistant prostate adenocarcinoma
03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's enrollment of 26 is below the median of 60 across 7,712 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed /assent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and protocol.
  • Male or female, aged 18 years or older.
  • Body weight >=30 kilograms (kg).
  • Histological or cytological documentation of an invasive that was diagnosed as locally advanced/ or and is of one of the following tumor types: a) Part 1: cutaneous melanoma; HNSCC (oral cavity, larynx, oropharynx, hypopharynx, nasal cavity/paranasal sinuses); non-small cell lung cancer (squamous and non-squamous); urothelial carcinoma of the upper and lower urinary tract; clear cell renal carcinoma; castrate resistant prostate adenocarcinoma. b) Part 2: HNSCC (oral cavity, larynx, pharynx, paranasal sinuses).
  • Part 1 only: Disease that has progressed after standard therapy for the specific tumor type, or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate, or if no further standard therapy exists, or where standard therapy is refused. May be /anti-PD-L1 experienced or naïve.
  • Part 2 only: Disease that has progressed after receiving platinum-based chemotherapy (unless medically or discontinued due to toxicity) and anti-PD-1/anti-PD-L1 therapy (in combination or as separate in either sequence).
  • per version 1.1 guidelines. Palpable lesions that are not measurable by radiographic or photographic evaluations may not be utilized as the only measurable lesion. Any measurable lesion biopsied at Screening cannot be followed as a target/index lesion unless agreed upon by GlaxoSmithKline (GSK).
  • (ECOG) Performance Status (PS) score of 0 or 1.
  • Adequate organ function.
  • A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions apply: a) Not a woman of (WOCBP); or, b) A WOCBP who agrees to follow the while receiving study intervention and for at least 180 days after the last dose of study intervention.
  • A male subject must agree to use a highly effective contraception while receiving study intervention and for at least 180 days after the last dose of study intervention and refrain from donating sperm during this period.
  • Agree to collection of tumor tissue: a) Part 1 and Part 2: collected any time from the initial diagnosis of invasive malignancy; a fresh tumor biopsy will be required if archival specimen is unavailable prior to first dose. b) Part 1 pharmacokinetic/pharmacodynamic cohort(s): Archival tissue as noted in point (a) above. Paired tumor biopsies: tumor tissue collected any time after completion of dosing of the last therapy and prior to first dose and an on-treatment biopsy. c) Part 2: A minimum of 15 subjects from each arm will be required to provide paired tumor biopsies (in addition to the archival tissues as noted in point (a) above): tumor tissue collected any time after completion of dosing of the last therapy and prior to first dose and an on-treatment biopsy.

Exclusion criteria

Exclusion Criteria:

  • Received prior treatment with the following therapies; calculation is based on date of last therapy to date of first dose of study intervention or SOC: a) Cytotoxic T-Lymphocyte-Associated Protein 4 ( [including tremelimumab] or Inducible T Cell Co-Stimulator (ICOS)-directed therapies at any time; b) >=4 lines of prior anticancer treatment: In subjects that relapse or progress within 1 year from the beginning of or concurrent therapy, the adjuvant/concurrent therapy is considered therapy; c) Systemic anticancer therapy or therapy within 30 days, or 5 half-lives, whichever is shorter; at least 14 days must have elapsed between the date of the last prior therapy to the date of first dose of study intervention or SOC.
  • Prior radiation therapy: permissible if at least one non-irradiated is available for assessment per v1.1 or if a solitary measurable lesion was irradiated, objective progression is documented. At least 14 days must have elapsed between the date of the last dosage of radiation and the first dose of study intervention/SOC.
  • Invasive or history of invasive malignancy other than disease under study within the last two years, except: a) Any other invasive malignancy for which the subject was definitively treated, has been disease-free for \<=2 years and in the opinion of the Investigator and Medical Monitor will not affect the evaluation of the effects of the study intervention or SOC on the currently targeted malignancy, may be included in this clinical study; Curatively treated non-melanoma skin cancer or successfully treated in-situ carcinoma.
  • Toxicity from previous anticancer treatment that includes: a) >=Grade 3 toxicity considered related to prior immunotherapy and that led to treatment discontinuation; b) Toxicity related to prior treatment that has not resolved to \<=Grade 1 (except alopecia, vitiligo, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be \<=Grade 2).
  • Central nervous system (CNS) , with the following exception: Subjects with previously treated who are clinically stable and had no requirement for during at least 14 days prior to first dose of study intervention or SOC.
  • Major surgery \<=28 days of first dose of study intervention or SOC.
  • disease (current or history) or syndrome that required systemic treatment within the past 2 years. Replacement therapies which include physiological doses of corticosteroids for treatment of endocrinopathies (i.e., adrenal insufficiency) are not considered systemic treatments.
  • Recent history (within 24 weeks) of gastrointestinal obstruction that required surgery, acute diverticulitis, inflammatory bowel disease, or intra-abdominal abscess.
  • Receiving systemic steroids (>=10 milligrams [mg] oral prednisone or equivalent) or other agents within 7 days prior to first dose of study intervention or SOC.
  • Prior allogeneic/autologous bone marrow or solid organ transplantation.
  • Received live-virus vaccine within 30 days from start of study intervention or SOC.
  • Current or history of idiopathic pulmonary fibrosis, pneumonitis (for past, subject is excluded if steroids were required), interstitial lung disease or organizing pneumonia.
  • Recent history (within 24 weeks) of uncontrolled, symptomatic ascites, pleural or pericardial effusions.
  • History or evidence of cardiac abnormalities within the 24 weeks prior to enrollment which include: a) Serious uncontrolled cardiac arrhythmia or abnormalities including second degree (Type II) or third degree atrioventricular block. b) Cardiomyopathy, myocardial infarction, acute coronary syndromes (including unstable angina pectoris), coronary angioplasty, stenting, or bypass grafting. c) Symptomatic pericarditis.
  • Current unstable liver or biliary disease per Investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
  • Active infection requiring systemic therapy.
  • Known infection; positive test for active infection (presence of hepatitis B surface antigen) or active infection.
  • History of severe to monoclonal antibodies, the Standard of Care agents, including any ingredient used in the formulation, based on which treatment the subject is to receive.
  • Any serious and/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining or compliance to the study procedures, in the opinion of the Investigator.
  • For subjects receiving SOC: Requires therapy with a medication that may alter the PK of the SOC agent (e.g., strong inducers or inhibitors of cytochrome P (CYP)3A4 for subjects receiving docetaxel or paclitaxel) during the study treatment period. Please refer to the package insert for the agent the subject is to receive.
  • For subjects receiving SOC: Any , per the package insert and/or Institutional guidelines, to the treatment the subject is to receive.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Part 1: feladilimab +tremelimumab

    In Part 1, subjects with advanced selected solid tumors will be enrolled. Subjects will be administered escalating doses of feladilimab and tremelimumab in combination. feladilimab will be administered every 3 weeks and tremelimumab will be administered every 3 weeks for 6 doses and every 12 weeks thereafter.

    Drug: feladilimab · Drug: Tremelimumab

  • Experimental
    Part 2: feladilimab +tremelimumab

    In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered feladilimab in combination with tremelimumab at recommended Phase 2 dose as determined from Part 1.

    Drug: feladilimab · Drug: Tremelimumab

  • Active comparator
    Part 2: SOC

    In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered a single agent SOC therapy of either paclitaxel, docetaxel or cetuximab as per the investigators choice.

    Drug: Docetaxel · Drug: Paclitaxel · Drug: Cetuximab

Interventions

  • feladilimab is humanized anti-ICOS agonist immunoglobulin G (IgG) 4 monoclonal antibody (mAb), which will be administered as an intravenous (IV) infusion once every 3 weeks.

  • Tremelimumab is humanized anti-CTLA-4 IgG2 mAb, which will be administered as an IV infusion once every 3 weeks for 6 doses, thereafter once every 12 weeks .

  • Docetaxel is a microtubule stabilizer which will be administered as an IV infusion once every 3 weeks at a dose of 75 milligrams per meter square (mg/m\^2).

  • Paclitaxel is a microtubule stabilizer which will be administered as an IV infusion once weekly at a dose of 80 mg/m\^2.

  • Cetuximab is a recombinant, human/mouse chimeric anti-estimated glomerular filtration rate (EGFR) mAb. Cetuximab will be administered at a loading dose of 400 mg/m\^2 followed by 250 mg/m\^2 once weekly.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs)-Part 1

    A DLT is considered by the investigator to be clinically relevant, attributed event within first 28 days of intervention meeting the following criteria of toxicity, Hematologic: Febrile neutropenia, Grade 4 neutropenia of greater than (\>) 7 days in duration or requiring Granulocyte- Colony stimulating factor (G-CSF), Grade 4 anemia and Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia; Non-hematologic: Grade 4 toxicity, Grade 3 pneumonitis, any greater than or equal to (≥) Grade 2 pneumonitis that does not resolve to less than or equal to (≤ ) Grade 1 within 3 days of the initiation of maximal supportive care, Grade 3 toxicity that does not resolve to Grade 1 or baseline within 3 days despite optimal supportive care and any Grade 2 ocular toxicity requiring systemic steroids, or any ≥ Grade 3 ocular toxicity.

    Time frame: Up to 28 days

  2. Number of Participants With DLTs According to Severity-Part 1

    The severity of all toxicities were graded using the National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 5.0. Grade 1: Mild reaction; infusion interruption not indicated; intervention not indicated; Grade 2: Requires therapy or infusion interruption but responds promptly to symptomatic treatment or prophylactic medications indicated for ≤24 hours; Grade 3: Prolonged (i.e., not rapidly responsive to symptomatic medication and/or brief interruption of infusion) or recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae; Grade 4: Life-threatening; pressor or ventilatory support indicated; Grade 5: Death related to AE.

    Time frame: Up to 28 days

  3. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)-Part 1

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the subject or may require medical or surgical intervention/SOC to prevent one of the other outcomes mentioned before. AESIs are defined as events of potential immunologic etiology, including immune related AEs.

    Time frame: Up to 4 years

  4. Number of Participant With AE/SAE/DLTs Leading to Dose Modifications/Delays/Withdrawals-Part 1

    The number of participants with AE/SAE/DLTs leading to dose modifications/delays/withdrawals were summarized.

    Time frame: Up to 4 years

  5. Number of Participants With AEs, SAEs, AESIs According to Severity - Part 1

    The severity of all toxicities were graded using the National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 5.0. Grade 1: Mild reaction; infusion interruption not indicated; intervention not indicated; Grade 2: Requires therapy or infusion interruption but responds promptly to symptomatic treatment or prophylactic medications indicated for ≤24 hours; Grade 3: Prolonged (i.e., not rapidly responsive to symptomatic medication and/or brief interruption of infusion) or recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae; Grade 4: Life-threatening; pressor or ventilatory support indicated; Grade 5: Death related to AE.

    Time frame: Up to 4 years

  6. Number of Participants With Severe- AEs/SAEs/DLTs Leading to Dose Modifications/Delays/Withdrawals-Part 1

    The number of participants with severe- AE/SAE/DLTs leading to dose modifications/delays/withdrawals were summarized.

    Time frame: Up to 4 years

  7. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)-Part 1

    SBP and DBP were measured after 5 minutes of rest for the participant.

    Time frame: Baseline (Day 1) and Week 4

  8. Change From Baseline in Temperature-Part 1

    Temperature was measured after 5 minutes of rest for the participant.

    Time frame: Baseline (Day 1) and Week 4

  9. Change From Baseline in Pulse Rate-Part 1

    Pulse rate was measured after 5 minutes of rest for the participant.

    Time frame: Baseline (Day 1) and Week 4

  10. Change From Baseline in Respiratory Rate-Part 1

    Respiratory rate was measured after 5 minutes of rest for the participant.

    Time frame: Baseline (Day 1) and Week 4

  11. Change From Baseline in Oxygen Saturation-Part 1

    Oxygen saturation was measured using pulse oximeter after 5 minutes of rest for the participant.

    Time frame: Baseline (Day 1) and Week 4

  12. Number of Participants With Electrocardiogram (ECG) Findings

    Single 12-lead ECG was obtained using an automated ECG machine. ECG findings were categorized as: normal, abnormal - clinically significant (CS), or abnormal - not clinically significant (NCS), as determined by the investigator.

    Time frame: Baseline (Pre dose, Day 1) and up to 4 Years

  13. Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count-Part 1

    Blood samples were collected to assess change from Baseline in neutrophil, lymphocyte, monocyte, eosinophil, basophil and platelet counts.

    Time frame: Baseline (Day 1) and Week 4

  14. Change From Baseline in Hemoglobin Level-Part 1

    Blood samples were collected to assess change from baseline in hemoglobin level.

    Time frame: Baseline (Day 1) and Week 4

  15. Change From Baseline in Hematocrit Level-Part 1

    Blood samples were collected to assess change from baseline in hematocrit level.

    Time frame: Baseline (Day 1) and Week 4

  16. Change From Baseline in Erythrocytes Count-Part 1

    Blood samples were collected to assess change from baseline in Erythrocytes count.

    Time frame: Baseline (Day 1) and Week 4

  17. Change From Baseline in Albumin and Total Protein Levels-Part 1

    Blood samples were collected to assess change from Baseline in albumin and total protein levels.

    Time frame: Baseline (Day 1) and Week 4

  18. Change From Baseline in Creatinine and Bilirubin Levels-Part 1

    Blood samples were collected to assess change from baseline in creatinine and bilirubin levels.

    Time frame: Baseline (Day 1) and Week 4

  19. Change From Baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Lactate Dehydrogenase (LDH) Levels-Part 1

    Blood samples were collected to assess change from baseline in ALT, AST ALP, LDH levels.

    Time frame: Baseline (Day 1) and Week 4

  20. Change From Baseline in Amylase and Lipase Levels-Part 1

    Blood samples were collected to assess change from baseline in amylase and lipase levels.

    Time frame: Baseline (Day 1) and week 4

  21. Change From Baseline in Urea, Glucose, Potassium, Sodium and Calcium Levels-Part 1

    Blood samples were collected to assess change in levels of urea, glucose, potassium, sodium and calcium from baseline.

    Time frame: Baseline (Day 1) and Week 4

  22. Change From Baseline in Specific Gravity of Urine-Part 1

    Urine samples were collected to assess change from baseline in specific gravity of urine.

    Time frame: Baseline (Day 1) and Week 4

  23. Change From Baseline in Potential of Hydrogen (pH) of Urine-Part 1

    Urine samples were collected to assess change from baseline in pH of urine.

    Time frame: Baseline (Day 1) and Week 4

  24. Number of Participants With Abnormal Urinalysis Parameters-Part 1

    The dipstick test gives positive or negative results for protein, ketones, occult blood and glucose in urine. Positive test results were considered as abnormal. Number of participants with positive test results have been summarized.

    Time frame: Week 4

  25. Change From Baseline in Thyroid Stimulating Hormone (TSH) or Thyrotropin-Part 1

    Blood samples were collected to assess change from Baseline in TSH.

    Time frame: Baseline (Day 1) and Week 4

  26. Change From Baseline in Free Triiodothyronine (T3)-Part 1

    Blood samples were collected to assess change from Baseline in free T3.

    Time frame: Baseline (Day 1) and Week 4

  27. Change From Baseline in Free Thyroxine (T4)-Part 1

    Blood samples were collected to assess change from baseline in free T4.

    Time frame: Baseline (Day 1) and Week 4

  28. Overall Survival-Part 2

    For participants in Part 2, overall survival is defined as time from the date of randomization to the date of death due to any cause.

    Time frame: Up to 4 years

Secondary outcomes

  1. Overall Response Rate-Part 1

    Overall response rate is defined as percentage of participants with confirmed complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 millimeter \[mm\]) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) at any time as per response evaluation criteria in solid tumors (RECIST) version 1.1.

    Time frame: Up to 4 years

  2. Overall Response Rate-Part 2

    Overall response rate is defined as percentage of participants with confirmed complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) at any time as per RECIST version 1.1.

    Time frame: Up to 4 years

  3. Disease Control Rate-Part 1

    Disease control rate is defined as percentage of subjects with confirmed complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) or at least 18 weeks of stable disease (Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD) as per RECIST version 1.1.

    Time frame: Up to 4 years

  4. Disease Control Rate-Part 2

    Disease control rate is defined as percentage of subjects with confirmed complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) or at least 18 weeks of stable disease (Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD) as per RECIST version 1.1.

    Time frame: Up to 4 years

  5. Progression Free Survival-Part 2

    For Part 2, progression free survival duration is defined as the time from the date of randomization to first documented evidence of disease progression (At least a 20% increase in the sum of diameters of target lesions and In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm) or death (regardless of cause of death), whichever comes first as per RECIST version 1.1.

    Time frame: Up to 4 years

  6. Time to Response-Part 2

    Time to response is defined as the time from the first dose to the first documented evidence of complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) for participants with a confirmed CR or PR as per RECIST version 1.1.

    Time frame: Up to 4 years

  7. Duration of Response-Part 2

    Duration of response is defined as time from the first documented evidence of response until the first documented sign of disease progression or death among participants who achieve a response (CR \[Disappearance of all target lesions. Any pathological lymph nodes {whether target or non-target} must have reduction in short axis to \<10 mm or PR \[At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters\] as per RECIST version 1.1).

    Time frame: Up to 4 years

  8. Maximum Observed Plasma Concentration (Cmax) of Feladilimab-Part 1

    Blood samples were collected at indicated time points for pharmacokinetic assessment.

    Time frame: Pre-dose, end of infusion and 4 hours post dose at Day 1

  9. Cmax of Tremelimumab-Part 1

    Blood samples were collected at indicated time points for pharmacokinetic assessment.

    Time frame: Pre-dose, end of infusion and 4 hours post dose at Day 1

  10. Cmax of Feladilimab-Part 2

    Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.

    Time frame: Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, 19, 25, then every 12 weeks for 2 years; end of infusion at Weeks 1, 19 and 25; and 4 hours post-infusion at Week 1

  11. Cmax of Tremelimumab-Part 2

    Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.

    Time frame: Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, 19, 25, then every 12 weeks for 2 years; end of infusion at Weeks 1, 19 and 25; and 4 hours post-infusion at Week 1

  12. Minimum Observed Plasma Concentration (Cmin) of Feladilimab-Part 1

    Blood samples were collected at indicated time points for pharmacokinetic assessment.

    Time frame: Pre-dose, end of infusion and 4 hours post dose at Day 1

  13. Cmin of Tremelimumab-Part 1

    Blood samples were collected at indicated time points for pharmacokinetic assessment.

    Time frame: Pre-dose, end of infusion and 4 hours post dose at Day 1

  14. Cmin of Feladilimab-Part 2

    Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.

    Time frame: Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, then every 12 weeks for 2 years; end of infusion; and 4 hours post-infusion at Week 1

  15. Cmin of Tremelimumab-Part 2

    Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.

    Time frame: Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, then every 12 weeks for 2 years; end of infusion; and 4 hours post-infusion at Week 1

  16. Area Under the Plasma Concentration-time Curve (AUC[0-t]) of Feladilimab-Part 1

    Blood samples were collected at indicated time points for pharmacokinetic assessment.

    Time frame: Pre-dose, end of infusion and 4 hours post dose at Day 1

  17. AUC(0-t) of Tremelimumab-Part 1

    Blood samples were collected at indicated time points for pharmacokinetic assessment.

    Time frame: Pre-dose, end of infusion and 4 hours post dose at Day 1

  18. AUC(0-t) of Feladilimab-Part 2

    Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.

    Time frame: Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, 19, 25, then every 12 weeks for 2 years; end of infusion at Weeks 1, 19 and 25, and 4 hours post-infusion at Week 1

  19. AUC(0-t) of Tremelimumab-Part 2

    Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment

    Time frame: Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, then every 12 weeks for 2 years; end of infusion; and 4 hours post-infusion at Week 1

  20. Number of Participants With Anti-drug Antibodies Against Feladilimab-Part 1

    Serum samples were collected and tested for the presence of antibodies to feladilimab.

    Time frame: Pre-dose at Week 4, 7, 10 and 13

  21. Number of Participants With Anti-drug Antibodies Against Tremelimumab-Part 1

    Serum samples were collected and tested for the presence of antibodies to tremelimumab.

    Time frame: Pre-dose at Week 1, 4, 7, 10 and 13

  22. Number of Participants With Anti-drug Antibodies Against Feladilimab-Part 2

    Serum samples will be collected and tested for the presence of antibodies to feladilimab.

    Time frame: Up to 2.5 years

  23. Change From Baseline in Free T4-Part 2

    Blood samples will be collected to assess change from baseline in free T4.

    Time frame: Baseline and up to 2 years

  24. Number of Participants With Anti-drug Antibodies Against Tremelimumab-Part 2

    Serum samples will be collected and tested for the presence of antibodies to tremelimumab.

    Time frame: Up to 2.5 years

  25. Number of Participants With AEs, SAEs and AESI-Part 2

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the subject or may require medical or surgical intervention/SOC to prevent one of the other outcomes mentioned before. AESIs are defined as events of potential immunologic etiology, including immune related AEs.

    Time frame: Up to 4 years

  26. Number of Participants With AEs, SAEs, AESIs Based on Severity-Part 2

    The severity of all toxicities were graded using the National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 5.0. Grade 1: Mild reaction; infusion interruption not indicated; intervention not indicated; Grade 2: Requires therapy or infusion interruption but responds promptly to symptomatic treatment or prophylactic medications indicated for ≤24 hours; Grade 3: Prolonged (i.e., not rapidly responsive to symptomatic medication and/or brief interruption of infusion) or recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae; Grade 4: Life-threatening; pressor or ventilatory support indicated; Grade 5: Death related to AE

    Time frame: Up to 4 years

  27. Number of Participants With Severe- AEs/SAEs/DLTs Leading to Dose Modifications/Delays/Withdrawals-Part 2

    The number of participants with severe- AE/SAE/DLTs leading to dose modifications/delays/withdrawals were planned to be summarized.

    Time frame: Up to 4 years

  28. Change From Baseline in SBP and DBP-Part 2

    SBP and DBP will be measured after 5 minutes of rest for the participant.

    Time frame: Baseline and up to 2 years

  29. Change From Baseline in Temperature-Part 2

    Temperature will be measured after 5 minutes of rest for the participant.

    Time frame: Baseline and up to 2 years

  30. Change From Baseline in Pulse Rate-Part 2

    Pulse rate will be measured after 5 minutes of rest for the participant.

    Time frame: Baseline and up to 2 years

  31. Change From Baseline in Respiratory Rate-Part 2

    Respiratory rate will be measured after 5 minutes of rest for the participant.

    Time frame: Baseline and up to 2 years

  32. Change From Baseline in Oxygen Saturation-Part 2

    Oxygen saturation will be measured using pulse oximetry after 5 minutes of rest for the participant.

    Time frame: Baseline and up to 2 years

  33. Change From Baseline in ECG Measurement-Part 2

    Single 12-lead ECG will be obtained using an automated ECG machine.

    Time frame: Baseline (Pre-dose) up to 2 years

  34. Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count-Part 2

    Blood samples will be collected to assess change from baseline in neutrophil, lymphocyte, monocyte, eosinophil, basophil and platelet count.

    Time frame: Baseline and up to 2 years

  35. Change From Baseline in Hemoglobin Level-Part 2

    Blood samples will be collected to assess change from baseline in hemoglobin level.

    Time frame: Baseline and up to 2 years

  36. Change From Baseline in Hematocrit Level-Part 2

    Blood samples will be collected to assess change from baseline in hematocrit level.

    Time frame: Baseline and up to 2 years

  37. Change From Baseline in Erythrocytes Count-Part 2

    Blood samples will be collected to assess change from Baseline in erythrocytes count.

    Time frame: Baseline and up to 2 years

  38. Change From Baseline in Albumin and Total Protein Levels-Part 2

    Blood samples will be collected to assess change from baseline in albumin and total protein levels.

    Time frame: Baseline and up to 2 years

  39. Change From Baseline in Creatinine and Bilirubin Levels-Part 2

    Blood samples will be collected to assess change from baseline in creatinine and bilirubin levels.

    Time frame: Baseline and up to 2 years

  40. Change From Baseline in ALT, AST, ALP, LDH Levels-Part 2

    Blood samples will be collected to assess change from baseline in ALT, AST ALP, LDH, amylase and lipase levels.

    Time frame: Baseline and up to 2 years

  41. Change From Baseline in Amylase and Lipase Levels-Part 2

    Blood samples were collected to assess change from baseline in amylase and lipase levels.

    Time frame: Baseline and up to 2 years

  42. Change From Baseline in Urea, Glucose, Potassium, Sodium and Calcium Levels -Part 2

    Blood samples will be collected to assess change in levels of urea, glucose, potassium, sodium and calcium from baseline.

    Time frame: Baseline and up to 2 years

  43. Change From Baseline in Specific Gravity of Urine-Part 2

    Urine samples will be collected to assess change from Baseline in specific gravity of urine.

    Time frame: Baseline and up to 2 years

  44. Change From Baseline in pH of Urine-Part 2

    Urine samples will be collected to assess change from baseline in pH of urine.

    Time frame: Baseline and up to 2 years

  45. Number of Participants With Abnormal Urinalysis Parameters-Part 2

    The dipstick test gives positive or negative results for protein, ketones, occult blood and glucose. Positive test results were considered as abnormal. Number of participants with positive test results were planned to be summarized.

    Time frame: Up to 2 years

  46. Change From Baseline in TSH-Part 2

    Blood samples will be collected to assess change from Baseline in TSH.

    Time frame: Baseline and up to 2 years

  47. Change From Baseline in Free T3-Part 2

    Blood samples will be collected to assess change from baseline in free T3.

    Time frame: Baseline and up to 2 years

07

Results

Posted Aug 22, 2022
Limitations and caveats
The sponsor made the decision to not continue the study at the end of Part 1 based on the totality of available data due to lack of efficacy and not due to safety. Hence Part 2 was not initiated and participants were not enrolled in the same.

Participant flow

The study was conducted in United States and Canada.

Participant flow — Overall Study
MilestonePart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mgPart 2: Feladilimab +TremelimumabPart 2: Standard of Care (SOC)
Started11531600
Completed10431000
Not completed0110600
Withdrew: Lost to follow-up0000100
Withdrew: Withdrawal by subject0010200
Withdrew: Study terminated by sponsor0100300

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs)-Part 1

A DLT is considered by the investigator to be clinically relevant, attributed event within first 28 days of intervention meeting the following criteria of toxicity, Hematologic: Febrile neutropenia, Grade 4 neutropenia of greater than (\>) 7 days in duration or requiring Granulocyte- Colony stimulating factor (G-CSF), Grade 4 anemia and Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia; Non-hematologic: Grade 4 toxicity, Grade 3 pneumonitis, any greater than or equal to (≥) Grade 2 pneumonitis that does not resolve to less than or equal to (≤ ) Grade 1 within 3 days of the initiation of maximal supportive care, Grade 3 toxicity that does not resolve to Grade 1 or baseline within 3 days despite optimal supportive care and any Grade 2 ocular toxicity requiring systemic steroids, or any ≥ Grade 3 ocular toxicity.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs)-Part 1
ParticipantsPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Number of Participants With Dose Limiting Toxicities (DLTs)-Part 100001
PrimaryNumber of Participants With DLTs According to Severity-Part 1

The severity of all toxicities were graded using the National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 5.0. Grade 1: Mild reaction; infusion interruption not indicated; intervention not indicated; Grade 2: Requires therapy or infusion interruption but responds promptly to symptomatic treatment or prophylactic medications indicated for ≤24 hours; Grade 3: Prolonged (i.e., not rapidly responsive to symptomatic medication and/or brief interruption of infusion) or recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae; Grade 4: Life-threatening; pressor or ventilatory support indicated; Grade 5: Death related to AE.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Participants With DLTs According to Severity-Part 1
ParticipantsPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Grade 100000
Grade 200000
Grade 300001
Grade 400000
Grade 500000
PrimaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)-Part 1

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the subject or may require medical or surgical intervention/SOC to prevent one of the other outcomes mentioned before. AESIs are defined as events of potential immunologic etiology, including immune related AEs.

Time frame:
Up to 4 years
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)-Part 1
ParticipantsPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
AEs115316
SAEs00336
AESIs00207
PrimaryNumber of Participant With AE/SAE/DLTs Leading to Dose Modifications/Delays/Withdrawals-Part 1

The number of participants with AE/SAE/DLTs leading to dose modifications/delays/withdrawals were summarized.

Time frame:
Up to 4 years
Reported as:
Count of participants · Participants
Number of Participant With AE/SAE/DLTs Leading to Dose Modifications/Delays/Withdrawals-Part 1
ParticipantsPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Any Aes-Dose Modification00000
Any Aes-Dose Delay00304
Any Aes-Dose Withdrawal00103
Any SAEs-Dose Modification00000
Any SAEs-Dose Delay00101
Any SAEs-Dose Withdrawal00102
Any DLTs-Dose Modification00000
Any DLTs-Dose Delay00001
Any DLTs-Dose Withdrawal00001
PrimaryNumber of Participants With AEs, SAEs, AESIs According to Severity - Part 1

The severity of all toxicities were graded using the National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 5.0. Grade 1: Mild reaction; infusion interruption not indicated; intervention not indicated; Grade 2: Requires therapy or infusion interruption but responds promptly to symptomatic treatment or prophylactic medications indicated for ≤24 hours; Grade 3: Prolonged (i.e., not rapidly responsive to symptomatic medication and/or brief interruption of infusion) or recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae; Grade 4: Life-threatening; pressor or ventilatory support indicated; Grade 5: Death related to AE.

Time frame:
Up to 4 years
Reported as:
Count of participants · Participants
Number of Participants With AEs, SAEs, AESIs According to Severity - Part 1
ParticipantsPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Grade 1: AEs00004
Grade 2: AEs11104
Grade 3: AEs00336
Grade 4: AEs00101
Grade 5: AEs00001
Grade 1: SAEs00000
Grade 2: SAEs00001
Grade 3: SAEs00233
Grade 4: SAEs00101
Grade 5: SAEs00001
Grade 1: AESI00003
Grade 2: AESI00202
Grade 3: AESI00001
Grade 4: AESI00001
Grade 5: AESI00000
PrimaryNumber of Participants With Severe- AEs/SAEs/DLTs Leading to Dose Modifications/Delays/Withdrawals-Part 1

The number of participants with severe- AE/SAE/DLTs leading to dose modifications/delays/withdrawals were summarized.

Time frame:
Up to 4 years
Reported as:
Count of participants · Participants
Number of Participants With Severe- AEs/SAEs/DLTs Leading to Dose Modifications/Delays/Withdrawals-Part 1
ParticipantsPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Any Severe Aes-Dose Modification00000
Any Severe Aes-Dose Delay00304
Any Severe Aes-Dose Withdrawal00103
Any Severe SAEs-Dose Modification00000
Any Severe SAEs-Dose Delay00101
Any Severe SAEs-Dose Withdrawal00102
Any Severe DLTs-Dose Modification00000
Any Severe DLTs-Dose Delay00001
Any Severe DLTs-Dose Withdrawal00001
PrimaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)-Part 1

SBP and DBP were measured after 5 minutes of rest for the participant.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)-Part 1
Millimeters of mercury (mmHg)Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
SBP, Baseline (Day 1)104128128 ± 14.967133.67 ± 11.676127.5 ± 16.415
SBP, Week 416-12-10 ± 11.726-12 ± 11.533-0.27 ± 19.568
DBP, Baseline (Day 1)737983.4 ± 8.08174.67 ± 4.04176.25 ± 9.015
DBP, Week 44-3-5 ± 3.162-4 ± 6.557-2.8 ± 7.552
PrimaryChange From Baseline in Temperature-Part 1

Temperature was measured after 5 minutes of rest for the participant.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · Celsius (C)
Change From Baseline in Temperature-Part 1
Celsius (C)Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Baseline (Day 1)36.536.936.8 ± 0.21236.6 ± 0.17336.64 ± 0.479
Week 40-0.30.04 ± 0.3210.2 ± 0.10.04 ± 0.378
PrimaryChange From Baseline in Pulse Rate-Part 1

Pulse rate was measured after 5 minutes of rest for the participant.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · beats/minute
Change From Baseline in Pulse Rate-Part 1
beats/minutePart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Baseline (Day 1)818391.6 ± 29.77179.67 ± 9.07476.56 ± 14.724
Week 410-2.4 ± 20.7325 ± 15.7168.07 ± 10.747
PrimaryChange From Baseline in Respiratory Rate-Part 1

Respiratory rate was measured after 5 minutes of rest for the participant.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · breaths/ minute
Change From Baseline in Respiratory Rate-Part 1
breaths/ minutePart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Baseline (Day 1)181817.6 ± 0.89416 ± 016.75 ± 1.065
Week 40-20 ± 1.4142 ± 00.07 ± 1.668
PrimaryChange From Baseline in Oxygen Saturation-Part 1

Oxygen saturation was measured using pulse oximeter after 5 minutes of rest for the participant.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · Percentage (%) of Oxygen
Change From Baseline in Oxygen Saturation-Part 1
Percentage (%) of OxygenPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Baseline (Day 1)969595.6 ± 2.88196 ± 1.0097.63 ± 1.586
Week 4250.8 ± 1.3040 ± 2.00-0.2 ± 2.007
PrimaryNumber of Participants With Electrocardiogram (ECG) Findings

Single 12-lead ECG was obtained using an automated ECG machine. ECG findings were categorized as: normal, abnormal - clinically significant (CS), or abnormal - not clinically significant (NCS), as determined by the investigator.

Time frame:
Baseline (Pre dose, Day 1) and up to 4 Years
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Findings
ParticipantsPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Baseline (Pre dose, Day 1) — Normal11116
Baseline (Pre dose, Day 1) — Abnormal CS00100
Baseline (Pre dose, Day 1) — Abnormal NCS003210
Worst case Post-Baseline — Normal00010
Worst case Post-Baseline — Abnormal CS00000
Worst case Post-Baseline — Abnormal NCS00012
PrimaryChange From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count-Part 1

Blood samples were collected to assess change from Baseline in neutrophil, lymphocyte, monocyte, eosinophil, basophil and platelet counts.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · 10^9 cells/liter
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count-Part 1
10^9 cells/literPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Basophils, Baseline (Day 1)0.000.000.05 ± 0.05770.01 ± 0.01410.039 ± 0.048
Basophils, Week 40.00—0 ± 00.005 ± 0.00710.007 ± 0.0344
Eosinophils, Baseline (Day 1)0.30.10.35 ± 0.1730.08 ± 0.1130.2 ± 0.217
Eosinophils, Week 40.4—0.03 ± 0.150.06 ± 0.0640.07 ± 0.169
Lymphocytes, Baseline (Day 1)11.50.9 ± 0.2161.25 ± 0.2120.92 ± 0.223
Lymphocytes, Week 40.4—0.23 ± 0.15-0.38 ± 0.460.01 ± 0.185
Monocytes, Baseline (Day 1)0.40.30.8 ± 0.29441.255 ± 0.91220.738 ± 0.3004
Monocytes, Week 40—0.05 ± 0.1732-0.215 ± 0.12020.038 ± 0.2598
Neutrophils, Baseline (Day 1)43.94.38 ± 1.5486.2 ± 2.9711.32 ± 21.379
Neutrophils, Week 40.3—0.93 ± 0.512-0.9 ± 0.7-8.95 ± 26.151
Platelets, Baseline (Day 1)196325250.6 ± 103.5229.7 ± 147.06266.3 ± 90.28
Platelets, Week 4-1—8.6 ± 34.93-8.7 ± 16.6531.3 ± 42.72
PrimaryChange From Baseline in Hemoglobin Level-Part 1

Blood samples were collected to assess change from baseline in hemoglobin level.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · grams/liter
Change From Baseline in Hemoglobin Level-Part 1
grams/literPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Baseline (Day 1)125134123.4 ± 32.61125 ± 23.07111.5 ± 12.74
Week 45—-5.8 ± 4.210.3 ± 2.89-0.7 ± 10.78
PrimaryChange From Baseline in Hematocrit Level-Part 1

Blood samples were collected to assess change from baseline in hematocrit level.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · fraction of 1
Change From Baseline in Hematocrit Level-Part 1
fraction of 1Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Baseline (Day 1)0.380.40.385 ± 0.109990.3937 ± 0.06470.3421 ± 0.03603
Week 40—-0.0202 ± 0.01494-0.0017 ± 0.01102-0.0039 ± 0.03413
PrimaryChange From Baseline in Erythrocytes Count-Part 1

Blood samples were collected to assess change from baseline in Erythrocytes count.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · 10^12 cells/liter
Change From Baseline in Erythrocytes Count-Part 1
10^12 cells/literPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Baseline (Day 1)4.24.654.328 ± 1.25924.673 ± 0.48853.76 ± 0.526
Week 40.13—-0.216 ± 0.21310.04 ± 0.16520.016 ± 0.3913
PrimaryChange From Baseline in Albumin and Total Protein Levels-Part 1

Blood samples were collected to assess change from Baseline in albumin and total protein levels.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · grams/Liter
Change From Baseline in Albumin and Total Protein Levels-Part 1
grams/LiterPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Albumin, Baseline (Day 1)414036 ± 7.1836.7 ± 9.2437.9 ± 2.79
Albumin, Week 40—0 ± 3.81-0.7 ± 2.31-2.1 ± 2.81
Protein, Baseline (Day 1)71—66.7 ± 7.0273 ± 3.6172.1 ± 6.51
Protein, Week 4——3.3 ± 2.890 ± 4.361.4 ± 4.31
PrimaryChange From Baseline in Creatinine and Bilirubin Levels-Part 1

Blood samples were collected to assess change from baseline in creatinine and bilirubin levels.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · micromoles/ Liter
Change From Baseline in Creatinine and Bilirubin Levels-Part 1
micromoles/ LiterPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Bilirubin, Baseline (Day 1)576.1 ± 2.446.1 ± 2.846.5 ± 4.23
Bilirubin, Week 4-1—2.2 ± 2.48-1.1 ± 1.97-0.4 ± 1.52
Creatinine, Baseline (Day 1)590006300031636.7 ± 43702.4473.5 ± 33.5293 ± 44.72
Creatinine, Week 41000—-1798.9 ± 3493.563.1 ± 4.29-2.9 ± 9.53
PrimaryChange From Baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Lactate Dehydrogenase (LDH) Levels-Part 1

Blood samples were collected to assess change from baseline in ALT, AST ALP, LDH levels.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · International Units/milliliter
Change From Baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Lactate Dehydrogenase (LDH) Levels-Part 1
International Units/milliliterPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
ALP, Baseline (Day 1)5368307.4 ± 416.93121.5 ± 82.73120.2 ± 60.54
ALP, Week 42—55.8 ± 101.74-18 ± 25.4636.2 ± 75.58
ALT, Baseline (Day 1)182524 ± 14.1826.7 ± 24.7918.2 ± 13.49
ALT, Week 4-2—8.2 ± 13.05-4.7 ± 15.147.4 ± 26.46
AST, Baseline (Day 1)324424.6 ± 9.9123.7 ± 15.8921.9 ± 8.23
AST, Week 40—10 ± 14.2-7 ± 14.7312.9 ± 35.1
LDH, Baseline (Day 1)325382228.8 ± 20.69168 ± 104.23239.9 ± 139.36
LDH, Week 4127—11.4 ± 42.7631.3 ± 53.342.9 ± 85.66
PrimaryChange From Baseline in Amylase and Lipase Levels-Part 1

Blood samples were collected to assess change from baseline in amylase and lipase levels.

Time frame:
Baseline (Day 1) and week 4
Reported as:
Mean · Units/milliliter
Change From Baseline in Amylase and Lipase Levels-Part 1
Units/milliliterPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Amylase, Baseline (Day 1)485050.2 ± 34.8540 ± 15.6251.5 ± 26.72
Amylase, Week 4-2—-5.3 ± 7.23-5 ± 1-3.5 ± 9.64
Lipase, Baseline (Day 1)282350.8 ± 55.6554.7 ± 48.9934.6 ± 27.8
Lipase, Week 40—1.5 ± 4.65-13 ± 23.816.1 ± 35.96
PrimaryChange From Baseline in Urea, Glucose, Potassium, Sodium and Calcium Levels-Part 1

Blood samples were collected to assess change in levels of urea, glucose, potassium, sodium and calcium from baseline.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · millimoles/Liter
Change From Baseline in Urea, Glucose, Potassium, Sodium and Calcium Levels-Part 1
millimoles/LiterPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Glucose, Baseline (Day 1)6.77.36.09 ± 1.69945.897 ± 0.27546.397 ± 1.5963
Glucose, Week 4-0.3—-0.365 ± 1.3225-0.848 ± 0.4949-0.11 ± 1.0164
Calcium, Baseline (Day 1)2.372.242.325 ± 0.12212.397 ± 0.14752.33 ± 0.0886
Calcium, Week 40.15—0.137 ± 0.13850.05 ± 0.1322-0.028 ± 0.0878
Potassium, Baseline (Day 1)4.344.18 ± 0.6064.3 ± 0.1734.22 ± 0.391
Potassium, Week 4-0.3—0.04 ± 0.586-0.03 ± 0.306-0.01 ± 0.328
Sodium, Baseline (Day 1)138140137.2 ± 4.49137.3 ± 3.21137.1 ± 3.52
Sodium, Week 4-1—0.2 ± 1.30.7 ± 0.58-1 ± 2.65
Urea, Baseline (Day 1)3.43.36.36 ± 1.2267.36 ± 0.756.92 ± 3.495
Urea, Week 41.5—-1.37 ± 1.091.08 ± 0.357-0.51 ± 1.633
PrimaryChange From Baseline in Specific Gravity of Urine-Part 1

Urine samples were collected to assess change from baseline in specific gravity of urine.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · Ratio
Change From Baseline in Specific Gravity of Urine-Part 1
RatioPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Baseline (Day 1)1.0151.021.0204 ± 0.008561.021 ± 0.010151.0159 ± 0.00605
Week 40.005—-0.0055 ± 0.006660.0013 ± 0.00115-0.0005 ± 0.006
PrimaryChange From Baseline in Potential of Hydrogen (pH) of Urine-Part 1

Urine samples were collected to assess change from baseline in pH of urine.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · pH
Change From Baseline in Potential of Hydrogen (pH) of Urine-Part 1
pHPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Baseline (Day 1)6.576 ± 1.1735.33 ± 0.2896.16 ± 0.826
Week 4-0.5—0.5 ± 0.707-0.33 ± 0.289-0.24 ± 0.918
PrimaryNumber of Participants With Abnormal Urinalysis Parameters-Part 1

The dipstick test gives positive or negative results for protein, ketones, occult blood and glucose in urine. Positive test results were considered as abnormal. Number of participants with positive test results have been summarized.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Urinalysis Parameters-Part 1
ParticipantsPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Dip stick test for Glucose0—102
Dip stick test for Protein0—106
Dip stick test for Occult Blood1—215
Dip stick test for Ketones0—403
PrimaryChange From Baseline in Thyroid Stimulating Hormone (TSH) or Thyrotropin-Part 1

Blood samples were collected to assess change from Baseline in TSH.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · milliUnits/Liter
Change From Baseline in Thyroid Stimulating Hormone (TSH) or Thyrotropin-Part 1
milliUnits/LiterPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Baseline (Day 1)0.791.221.856 ± 1.60611.463 ± 1.20792.211 ± 1.7527
Week 4———-0.87—
PrimaryChange From Baseline in Free Triiodothyronine (T3)-Part 1

Blood samples were collected to assess change from Baseline in free T3.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · Picomoles per liter
Change From Baseline in Free Triiodothyronine (T3)-Part 1
Picomoles per literPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Baseline (Day 1)3.53.62.75 ± 0.2124.473.88 ± 0.665
PrimaryChange From Baseline in Free Thyroxine (T4)-Part 1

Blood samples were collected to assess change from baseline in free T4.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · Picomoles per liter
Change From Baseline in Free Thyroxine (T4)-Part 1
Picomoles per literPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Baseline (Day 1)101112.43 ± 3.12813.84 ± 2.29615.98 ± 3.144
Week 4———2.57—
PrimaryOverall Survival-Part 2

For participants in Part 2, overall survival is defined as time from the date of randomization to the date of death due to any cause.

Time frame:
Up to 4 years

No measurements were reported for this outcome.

SecondaryOverall Response Rate-Part 1

Overall response rate is defined as percentage of participants with confirmed complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 millimeter \[mm\]) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) at any time as per response evaluation criteria in solid tumors (RECIST) version 1.1.

Time frame:
Up to 4 years
Reported as:
Number · Percentage of Participants
Overall Response Rate-Part 1
Percentage of ParticipantsPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Overall Response Rate-Part 10 (0 to 97.5)0 (0 to 97.5)0 (0 to 52.2)0 (0 to 70.8)6.3 (0.2 to 30.2)
SecondaryOverall Response Rate-Part 2

Overall response rate is defined as percentage of participants with confirmed complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) at any time as per RECIST version 1.1.

Time frame:
Up to 4 years

No measurements were reported for this outcome.

SecondaryDisease Control Rate-Part 1

Disease control rate is defined as percentage of subjects with confirmed complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) or at least 18 weeks of stable disease (Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD) as per RECIST version 1.1.

Time frame:
Up to 4 years
Reported as:
Number · Percentage of Participants
Disease Control Rate-Part 1
Percentage of ParticipantsPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Disease Control Rate-Part 10 (0 to 97.5)0 (0 to 97.5)0 (0 to 52.2)33.3 (0.8 to 90.6)12.5 (1.6 to 38.3)
SecondaryDisease Control Rate-Part 2

Disease control rate is defined as percentage of subjects with confirmed complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) or at least 18 weeks of stable disease (Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD) as per RECIST version 1.1.

Time frame:
Up to 4 years

No measurements were reported for this outcome.

SecondaryProgression Free Survival-Part 2

For Part 2, progression free survival duration is defined as the time from the date of randomization to first documented evidence of disease progression (At least a 20% increase in the sum of diameters of target lesions and In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm) or death (regardless of cause of death), whichever comes first as per RECIST version 1.1.

Time frame:
Up to 4 years

No measurements were reported for this outcome.

SecondaryTime to Response-Part 2

Time to response is defined as the time from the first dose to the first documented evidence of complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) for participants with a confirmed CR or PR as per RECIST version 1.1.

Time frame:
Up to 4 years

No measurements were reported for this outcome.

SecondaryDuration of Response-Part 2

Duration of response is defined as time from the first documented evidence of response until the first documented sign of disease progression or death among participants who achieve a response (CR \[Disappearance of all target lesions. Any pathological lymph nodes {whether target or non-target} must have reduction in short axis to \<10 mm or PR \[At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters\] as per RECIST version 1.1).

Time frame:
Up to 4 years

No measurements were reported for this outcome.

SecondaryMaximum Observed Plasma Concentration (Cmax) of Feladilimab-Part 1

Blood samples were collected at indicated time points for pharmacokinetic assessment.

Time frame:
Pre-dose, end of infusion and 4 hours post dose at Day 1
Reported as:
Geometric mean · nanograms/milliliter
Maximum Observed Plasma Concentration (Cmax) of Feladilimab-Part 1
nanograms/milliliterPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Maximum Observed Plasma Concentration (Cmax) of Feladilimab-Part 1275859652686.6 ± 25.728340.9 ± 12.36098.3 ± 25.3
SecondaryCmax of Tremelimumab-Part 1

Blood samples were collected at indicated time points for pharmacokinetic assessment.

Time frame:
Pre-dose, end of infusion and 4 hours post dose at Day 1
Reported as:
Geometric mean · nanograms/milliliter
Cmax of Tremelimumab-Part 1
nanograms/milliliterPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Cmax of Tremelimumab-Part 100112312.1 ± 8.2—93206.7 ± 24.8
SecondaryCmax of Feladilimab-Part 2

Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.

Time frame:
Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, 19, 25, then every 12 weeks for 2 years; end of infusion at Weeks 1, 19 and 25; and 4 hours post-infusion at Week 1

No measurements were reported for this outcome.

SecondaryCmax of Tremelimumab-Part 2

Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.

Time frame:
Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, 19, 25, then every 12 weeks for 2 years; end of infusion at Weeks 1, 19 and 25; and 4 hours post-infusion at Week 1

No measurements were reported for this outcome.

SecondaryMinimum Observed Plasma Concentration (Cmin) of Feladilimab-Part 1

Blood samples were collected at indicated time points for pharmacokinetic assessment.

Time frame:
Pre-dose, end of infusion and 4 hours post dose at Day 1
Reported as:
Geometric mean · nanograms/ milliliter
Minimum Observed Plasma Concentration (Cmin) of Feladilimab-Part 1
nanograms/ milliliterPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Minimum Observed Plasma Concentration (Cmin) of Feladilimab-Part 1462—348 ± 14.23197 ± 31856.4 ± 35.9
SecondaryCmin of Tremelimumab-Part 1

Blood samples were collected at indicated time points for pharmacokinetic assessment.

Time frame:
Pre-dose, end of infusion and 4 hours post dose at Day 1
Reported as:
Geometric mean · nanograms/ milliliter
Cmin of Tremelimumab-Part 1
nanograms/ milliliterPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Cmin of Tremelimumab-Part 16467—22466.3 ± 58.45715.6 ± 43.915084.9 ± 48.4
SecondaryCmin of Feladilimab-Part 2

Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.

Time frame:
Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, then every 12 weeks for 2 years; end of infusion; and 4 hours post-infusion at Week 1

No measurements were reported for this outcome.

SecondaryCmin of Tremelimumab-Part 2

Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.

Time frame:
Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, then every 12 weeks for 2 years; end of infusion; and 4 hours post-infusion at Week 1

No measurements were reported for this outcome.

SecondaryArea Under the Plasma Concentration-time Curve (AUC[0-t]) of Feladilimab-Part 1

Blood samples were collected at indicated time points for pharmacokinetic assessment.

Time frame:
Pre-dose, end of infusion and 4 hours post dose at Day 1
Reported as:
Geometric mean · nanograms*hours/milliLiter
Area Under the Plasma Concentration-time Curve (AUC[0-t]) of Feladilimab-Part 1
nanograms*hours/milliLiterPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Area Under the Plasma Concentration-time Curve (AUC[0-t]) of Feladilimab-Part 1545097.4—453561.5 ± 11.74552653.1 ± 18.51055659.5 ± 23.5
SecondaryAUC(0-t) of Tremelimumab-Part 1

Blood samples were collected at indicated time points for pharmacokinetic assessment.

Time frame:
Pre-dose, end of infusion and 4 hours post dose at Day 1
Reported as:
Geometric mean · nanograms*hours/milliLiter
AUC(0-t) of Tremelimumab-Part 1
nanograms*hours/milliLiterPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
AUC(0-t) of Tremelimumab-Part 1————18160725.7 ± 23.4
SecondaryAUC(0-t) of Feladilimab-Part 2

Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.

Time frame:
Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, 19, 25, then every 12 weeks for 2 years; end of infusion at Weeks 1, 19 and 25, and 4 hours post-infusion at Week 1

No measurements were reported for this outcome.

SecondaryAUC(0-t) of Tremelimumab-Part 2

Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment

Time frame:
Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, then every 12 weeks for 2 years; end of infusion; and 4 hours post-infusion at Week 1

No measurements were reported for this outcome.

SecondaryNumber of Participants With Anti-drug Antibodies Against Feladilimab-Part 1

Serum samples were collected and tested for the presence of antibodies to feladilimab.

Time frame:
Pre-dose at Week 4, 7, 10 and 13
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies Against Feladilimab-Part 1
ParticipantsPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Week 400105
Week 700102
Week 1000101
Week 1300001
SecondaryNumber of Participants With Anti-drug Antibodies Against Tremelimumab-Part 1

Serum samples were collected and tested for the presence of antibodies to tremelimumab.

Time frame:
Pre-dose at Week 1, 4, 7, 10 and 13
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies Against Tremelimumab-Part 1
ParticipantsPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mg
Week 100000
Week 400012
Week 701001
Week 1001000
Week 1300000
SecondaryNumber of Participants With Anti-drug Antibodies Against Feladilimab-Part 2

Serum samples will be collected and tested for the presence of antibodies to feladilimab.

Time frame:
Up to 2.5 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in Free T4-Part 2

Blood samples will be collected to assess change from baseline in free T4.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With Anti-drug Antibodies Against Tremelimumab-Part 2

Serum samples will be collected and tested for the presence of antibodies to tremelimumab.

Time frame:
Up to 2.5 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With AEs, SAEs and AESI-Part 2

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the subject or may require medical or surgical intervention/SOC to prevent one of the other outcomes mentioned before. AESIs are defined as events of potential immunologic etiology, including immune related AEs.

Time frame:
Up to 4 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With AEs, SAEs, AESIs Based on Severity-Part 2

The severity of all toxicities were graded using the National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 5.0. Grade 1: Mild reaction; infusion interruption not indicated; intervention not indicated; Grade 2: Requires therapy or infusion interruption but responds promptly to symptomatic treatment or prophylactic medications indicated for ≤24 hours; Grade 3: Prolonged (i.e., not rapidly responsive to symptomatic medication and/or brief interruption of infusion) or recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae; Grade 4: Life-threatening; pressor or ventilatory support indicated; Grade 5: Death related to AE

Time frame:
Up to 4 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With Severe- AEs/SAEs/DLTs Leading to Dose Modifications/Delays/Withdrawals-Part 2

The number of participants with severe- AE/SAE/DLTs leading to dose modifications/delays/withdrawals were planned to be summarized.

Time frame:
Up to 4 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in SBP and DBP-Part 2

SBP and DBP will be measured after 5 minutes of rest for the participant.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in Temperature-Part 2

Temperature will be measured after 5 minutes of rest for the participant.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in Pulse Rate-Part 2

Pulse rate will be measured after 5 minutes of rest for the participant.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in Respiratory Rate-Part 2

Respiratory rate will be measured after 5 minutes of rest for the participant.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in Oxygen Saturation-Part 2

Oxygen saturation will be measured using pulse oximetry after 5 minutes of rest for the participant.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in ECG Measurement-Part 2

Single 12-lead ECG will be obtained using an automated ECG machine.

Time frame:
Baseline (Pre-dose) up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count-Part 2

Blood samples will be collected to assess change from baseline in neutrophil, lymphocyte, monocyte, eosinophil, basophil and platelet count.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in Hemoglobin Level-Part 2

Blood samples will be collected to assess change from baseline in hemoglobin level.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in Hematocrit Level-Part 2

Blood samples will be collected to assess change from baseline in hematocrit level.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in Erythrocytes Count-Part 2

Blood samples will be collected to assess change from Baseline in erythrocytes count.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in Albumin and Total Protein Levels-Part 2

Blood samples will be collected to assess change from baseline in albumin and total protein levels.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in Creatinine and Bilirubin Levels-Part 2

Blood samples will be collected to assess change from baseline in creatinine and bilirubin levels.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in ALT, AST, ALP, LDH Levels-Part 2

Blood samples will be collected to assess change from baseline in ALT, AST ALP, LDH, amylase and lipase levels.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in Amylase and Lipase Levels-Part 2

Blood samples were collected to assess change from baseline in amylase and lipase levels.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in Urea, Glucose, Potassium, Sodium and Calcium Levels -Part 2

Blood samples will be collected to assess change in levels of urea, glucose, potassium, sodium and calcium from baseline.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in Specific Gravity of Urine-Part 2

Urine samples will be collected to assess change from Baseline in specific gravity of urine.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in pH of Urine-Part 2

Urine samples will be collected to assess change from baseline in pH of urine.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With Abnormal Urinalysis Parameters-Part 2

The dipstick test gives positive or negative results for protein, ketones, occult blood and glucose. Positive test results were considered as abnormal. Number of participants with positive test results were planned to be summarized.

Time frame:
Up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in TSH-Part 2

Blood samples will be collected to assess change from Baseline in TSH.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline in Free T3-Part 2

Blood samples will be collected to assess change from baseline in free T3.

Time frame:
Baseline and up to 2 years

No measurements were reported for this outcome.

Adverse events

Collected over Non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected from Day 1 to upto 4 years. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg0/1 (0%)0/1 (0%)1/1 (100%)
Part 1: Feladilimab 24 mg + Tremelimumab 75 mg0/1 (0%)0/1 (0%)1/1 (100%)
Part 1: Feladilimab 8 mg + Tremelimumab 225 mg0/5 (0%)3/5 (60%)5/5 (100%)
Part 1: Feladilimab 80 mg + Tremelimumab 75 mg0/3 (0%)3/3 (100%)3/3 (100%)
Part 1: Feladilimab 24 mg + Tremelimumab 225 mg1/16 (6.3%)6/16 (37.5%)16/16 (100%)
Part 2: Feladilimab + Tremelimumab———
Part 2: Standard of Care (SOC)———
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mgPart 2: Feladilimab + TremelimumabPart 2: Standard of Care (SOC)
PneumoniaInfections and infestations0/10/10/51/30/16——
Bone painMusculoskeletal and connective tissue disorders0/10/10/51/30/16——
HypoxiaRespiratory, thoracic and mediastinal disorders0/10/10/51/30/16——
EmbolismVascular disorders0/10/11/51/30/16——
Cardiac tamponadeCardiac disorders0/10/11/50/30/16——
BacteraemiaInfections and infestations0/10/11/50/30/16——
HyponatraemiaMetabolism and nutrition disorders0/10/11/50/30/16——
Pericardial effusion malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/10/11/50/30/16——
DyspnoeaRespiratory, thoracic and mediastinal disorders0/10/11/50/30/16——
ColitisGastrointestinal disorders0/10/10/50/31/16——
Most frequent other events
Showing 10 of 110
Most frequent other events
EventPart 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mgPart 2: Feladilimab + TremelimumabPart 2: Standard of Care (SOC)
DiarrhoeaGastrointestinal disorders1/10/11/50/38/16——
DyspepsiaGastrointestinal disorders1/10/11/50/30/16——
NauseaGastrointestinal disorders1/10/11/51/36/16——
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/10/10/50/31/16——
HaemothoraxRespiratory, thoracic and mediastinal disorders0/11/10/50/30/16——
Pleural effusionRespiratory, thoracic and mediastinal disorders0/11/10/50/30/16——
DyspnoeaRespiratory, thoracic and mediastinal disorders0/10/12/52/32/16——
FatigueGeneral disorders0/10/11/51/310/16——
AnaemiaBlood and lymphatic system disorders0/10/12/51/35/16——
Decreased appetiteMetabolism and nutrition disorders0/10/11/51/36/16——

Baseline characteristics

The sponsor made the decision to not continue the study at the end of Part 1 based on the totality of available data due to lack of efficacy and not due to safety. Hence Part 2 was not initiated and participants were not enrolled.

Age, Continuous
Age, Continuous(YEARS)Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mgPart 2: Feladilimab + TremelimumabPart 2: Standard of Care (SOC)Total
Mean51.0 ± 051.0 ± 058.2 ± 11.7369.0 ± 12.7766.8 ± 11.51——64.2 ± 11.95
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mgPart 2: Feladilimab + TremelimumabPart 2: Standard of Care (SOC)Total
Female11304009
Male0023120017
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 75 mgPart 1: Feladilimab 8 mg + Tremelimumab 225 mgPart 1: Feladilimab 80 mg + Tremelimumab 75 mgPart 1: Feladilimab 24 mg + Tremelimumab 225 mgPart 2: Feladilimab + TremelimumabPart 2: Standard of Care (SOC)Total
Black or African American00001001
Multiple00001001
White - White/Caucasian/European Heritage1153140024
08

Study locations

8 sites
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    New York, New York 10016-4744, United States
  • GSK Investigational Site
    New York, New York 10032, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15232, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Melbourne, Victoria 3000, Australia
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
09

References and documents

Publications

  • Hilton JF, Ott PA, Hansen AR, Li Z, Mathew M, Messina CH, Dave V, Ji X, Karpinich NO, Hirschfeld S, Ballas M, Zandberg DP. INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. Cancer Immunol Immunother. 2024 Feb 13;73(3):44. doi: 10.1007/s00262-023-03623-z. PubMed 38349570 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Jun 2021, 30 months.

Results were first posted in Aug 2022, 1 year 1 month after primary completion.

Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 30 months is below that.

Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2018
First posted
Oct 3, 2018
StartActual
Nov 26, 2018
Primary completionActual
Jun 25, 2021
CompletionActual
Sep 16, 2021
Results first posted
Aug 22, 2022
Last update
Aug 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03693612
Lead sponsor
GlaxoSmithKline
Collaborators
MedImmune LLC
Responsible party
Sponsor
First posted
Oct 3, 2018
Start date
Nov 26, 2018
Primary completion
Jun 25, 2021
Completion
Sep 16, 2021
Results posted
Aug 22, 2022
Last update
Aug 28, 2024

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Feladilimab

Start the discussion